Back to search
FDAFDA · Food and drugs·Recall number Z-1328-2013

Iris Diagnostics Division iQ Control/Focus Set, Part Number 800-3104, Lot Number 153-12. Product Usage: For in vitro diagnostic use with the iQ200 series.

Published May 22, 2013 · Recall initiated: September 18, 2012

Summary

FDA records medical device Class II recall Z-1328-2013, published May 22, 2013 and initiated September 18, 2012. Recalling firm: Iris Diagnostics; Status: Terminated; Reported quantity: 942 boxes; Lot: Part Number 800-3104. Lot Number 153-12. Expiration date: Jan 2013. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

The firm initiated this recall because complaints from customers reported that the recovery compared to assigned assay values is significantly below specification. This results in the instrument not passing controls and the customer not being able to run patient samples.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Iris Diagnostics
Distributor
Worldwide Distribution - USA Nationwide and the countries of: Canada, Malaysia, Spain, Switzerland, Taiwan, Peru, France, Russia, Japan, United Kingdom, Germany, and Paraguay.
Lot
Part Number 800-3104. Lot Number 153-12. Expiration date: Jan 2013
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Iris Diagnostics Division iQ Control/Focus Set, Part Number 800-3104, Lot Number 153-12. Product Usage: For in vitro diagnostic use with the iQ200 series. recalled?

Yes. FDA published recall Z-1328-2013 on May 22, 2013. Reported hazard: The firm initiated this recall because complaints from customers reported that the recovery compared to assigned assay values is significantly below specification. This results in the instrument not passing controls and the customer not being able to run patient samples.

What should I do if I have this product?

Voluntary: Firm initiated · Letter